Roche Convinces UK NICE On Cost-Benefit Of RoActemra For Giant Cell Arteritis
After an initial rejection, Roche's IL-6 drug RoActemra has received support from the UK's health technology assessment body to treat giant cell arteritis in a subset of patients, provided the treatment with the drug is permitted for one year at the most.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.